Covid 19 Infection clinical trials

Explore recruiting covid 19 infection clinical trials.

Recruiting covid 19 infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Covid 19 Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A clinical study of MK-1289 in healthy adult men (MK-1289-001)

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies

Italy

Therapeutic use (Phase IV) EU CTIS Study details

COVID-19 vaccine immunological studies in Finland

Finland

Therapeutic use (Phase IV) EU CTIS Study details

BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression

Italy, Poland, Spain, Finland, Germany, Romania +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (DAN-COVID)

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Covid 19 Infection trials by city

Covid 19 Infection in Toronto Covid 19 Infection in Vancouver Covid 19 Infection in Montreal Covid 19 Infection in Calgary Covid 19 Infection in Edmonton Covid 19 Infection in Ottawa Covid 19 Infection in Winnipeg Covid 19 Infection in Quebec City Covid 19 Infection in Hamilton Covid 19 Infection in Kitchener Covid 19 Infection in London Covid 19 Infection in Halifax Covid 19 Infection in New York Covid 19 Infection in Los Angeles Covid 19 Infection in Chicago Covid 19 Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease